Special Issue "Effects of Resveratrol Supplementation on Human Health and Disease"
A special issue of Nutrients (ISSN 2072-6643).
Deadline for manuscript submissions: closed (15 August 2017) | Viewed by 59300
It has been just over a decade since research regarding the health benefits of resveratrol captured the attention of the mainstream community. In 2006, David Sinclair’s laboratory published their findings that resveratrol supplementation improved health and survival of mice fed a high calorie diet. That same year, Baur and Sinclair published an instrumental review paper, which synthesized the available in vivo evidence to demonstrate that resveratrol had unprecedented potential to counter the development and progression of chronic disease, and could perhaps inspire the next class of “wonder drugs”. As news stories and online communities touted the promise of resveratrol, consumers found a health-related justification to drink red wine, while supplement companies found a new product to market. The pharmaceutical industry invested in resveratrol’s clinical promise through attempting to develop and test novel resveratrol formulations and analogues for treating disease in humans.
It is not surprising that clinical trials regarding resveratrol supplementation in humans began to emerge in 2007, with Boocock et al. demonstrating that dosages up to five grams per day were tolerable and safe in healthy humans. In the years since, resveratrol has endured a rollercoaster ride of controversy. Although early clinical trials generally seemed to support the beneficial cardiometabolic effects of a wide range of dosages of resveratrol supplementation, these initial studies were often limited in various ways. The enthusiasm for resveratrol was soon hampered by a few high-profile cases of research fraud, combined with an early termination to a multiple myeloma clinical trial examining a resveratrol formulation. Dozens of clinical trials have been performed since, exploring the effects of a wide range of resveratrol dosages on numerous clinical outcome measures across a diverse array of patient populations from around the world. While some of these results are indeed promising, there are plenty of disappointing results. Explanations for contradictory findings have ranged from criticisms of dosage selection and research methodology, to the notion that resveratrol does is not effective in healthy individuals, or that resveratrol simply does not produce the same physiologic effects in humans that it does in animal models. A number of fundamental questions tangential to clinical trial design have also continued to challenge researchers, such as resveratrol’s exact targets and mechanism(s) of action, the bioactivity of resveratrol’s metabolites, and whether its bioavailability is sufficient for it to have clinical applications.
There is now a wealth of information in the peer-review literature regarding resveratrol, yet the clinical utility of resveratrol remains uncertain. To gain a greater understanding of the effects of resveratrol on human health and disease, articles exploring a wide-range of topics are welcomed in this Special Issue of Nutrients. We welcome original research investing the clinical efficacy of resveratrol in various patient populations and its effects on healthy individuals, as well as synthesis papers that provide novel insights directly relevant to the clinical applications of resveratrol.
Dr. James M. Smoliga, DVM, PhD
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- red wine